Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease
Identifieur interne : 000944 ( Main/Corpus ); précédent : 000943; suivant : 000945Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease
Auteurs : H. Reichmann ; W. H. JostSource :
- European Journal of Neurology [ 1351-5101 ] ; 2010-09.
English descriptors
Abstract
Background: The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice. Methods: The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined. Results: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients. Conclusions: In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).
Url:
DOI: 10.1111/j.1468-1331.2010.02986.x
Links to Exploration step
ISTEX:5E8B3A4574D46E0EF8E935E2460D8529BBA7027BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title><author><name sortKey="Reichmann, H" sort="Reichmann, H" uniqKey="Reichmann H" first="H." last="Reichmann">H. Reichmann</name><affiliation><mods:affiliation>Department of Neurology, University of Dresden, Dresden</mods:affiliation></affiliation></author><author><name sortKey="Jost, W H" sort="Jost, W H" uniqKey="Jost W" first="W. H." last="Jost">W. H. Jost</name><affiliation><mods:affiliation>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5E8B3A4574D46E0EF8E935E2460D8529BBA7027B</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1468-1331.2010.02986.x</idno><idno type="url">https://api.istex.fr/document/5E8B3A4574D46E0EF8E935E2460D8529BBA7027B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000944</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title><author><name sortKey="Reichmann, H" sort="Reichmann, H" uniqKey="Reichmann H" first="H." last="Reichmann">H. Reichmann</name><affiliation><mods:affiliation>Department of Neurology, University of Dresden, Dresden</mods:affiliation></affiliation></author><author><name sortKey="Jost, W H" sort="Jost, W H" uniqKey="Jost W" first="W. H." last="Jost">W. H. Jost</name><affiliation><mods:affiliation>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-09">2010-09</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1164">1164</biblScope><biblScope unit="page" to="1171">1171</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">5E8B3A4574D46E0EF8E935E2460D8529BBA7027B</idno><idno type="DOI">10.1111/j.1468-1331.2010.02986.x</idno><idno type="ArticleID">ENE2986</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>combination therapy</term><term>monotherapy</term><term>quality of life</term><term>rasagiline</term><term>switch</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice. Methods: The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined. Results: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients. Conclusions: In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>H. Reichmann</name><affiliations><json:string>Department of Neurology, University of Dresden, Dresden</json:string></affiliations></json:item><json:item><name>W. H. Jost</name><affiliations><json:string>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>combination therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>monotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson’s disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>quality of life</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rasagiline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>switch</value></json:item></subject><articleId><json:string>ENE2986</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background: The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice. Methods: The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined. Results: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients. Conclusions: In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).</abstract><qualityIndicators><score>6.742</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1829</abstractCharCount><pdfWordCount>3826</pdfWordCount><pdfCharCount>25225</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>243</abstractWordCount></qualityIndicators><title>Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title><genre><json:string>article</json:string></genre><host><volume>17</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>8</total><last>1171</last><first>1164</first></pages><issn><json:string>1351-5101</json:string></issn><issue>9</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1468-1331.2010.02986.x</json:string></doi><id>5E8B3A4574D46E0EF8E935E2460D8529BBA7027B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5E8B3A4574D46E0EF8E935E2460D8529BBA7027B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5E8B3A4574D46E0EF8E935E2460D8529BBA7027B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5E8B3A4574D46E0EF8E935E2460D8529BBA7027B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title><author><persName><forename type="first">H.</forename><surname>Reichmann</surname></persName><affiliation>Department of Neurology, University of Dresden, Dresden</affiliation></author><author><persName><forename type="first">W. H.</forename><surname>Jost</surname></persName><affiliation>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-09"></date><biblScope unit="volume">17</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1164">1164</biblScope><biblScope unit="page" to="1171">1171</biblScope></imprint></monogr><idno type="istex">5E8B3A4574D46E0EF8E935E2460D8529BBA7027B</idno><idno type="DOI">10.1111/j.1468-1331.2010.02986.x</idno><idno type="ArticleID">ENE2986</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background: The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice. Methods: The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined. Results: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients. Conclusions: In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>combination therapy</term></item><item><term>monotherapy</term></item><item><term>Parkinson’s disease</term></item><item><term>quality of life</term></item><item><term>rasagiline</term></item><item><term>switch</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5E8B3A4574D46E0EF8E935E2460D8529BBA7027B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="09109"><doi origin="wiley">10.1111/ene.2010.17.issue-9</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue" number="9">9</numbering></numberingGroup><coverDate startDate="2010-09">September 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2010.02986.x</doi><idGroup><id type="unit" value="ENE2986"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><copyright>© 2010 The Author(s). European Journal of Neurology © 2010 EFNS</copyright><eventGroup><event type="firstOnline" date="2010-03-17"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-03-17"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.25 mode:FullText source:FullText result:FullText" date="2010-11-05"></event><event type="publishedOnlineFinalForm" date="2010-08-16"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-17"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1164">1164</numbering><numbering type="pageLast" number="1171">1171</numbering></numberingGroup><correspondenceTo>Prof. Dr. H. Reichmann, Department of Neurology, University of Dresden, Dresden, Germany (tel.: + 49 (0) 351/458‐3565; fax: +49 (0) 351 458 4365; e‐mail: <email normalForm="Heinz.Reichmann@uniklinikum-dresden.de">Heinz.Reichmann@uniklinikum‐dresden.de</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE2986.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 3 September 2009 Accepted 20 January 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="3"></count></countGroup><titleGroup><title type="main">Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title><title type="shortAuthors">H. Reichmann and W.H. Jost</title><title type="short">Rasagiline in daily clinical use</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>H.</givenNames><familyName>Reichmann</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>W. H.</givenNames><familyName>Jost</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Department of Neurology, University of Dresden, Dresden</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="DE"><unparsedAffiliation>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">combination therapy</keyword><keyword xml:id="k2">monotherapy</keyword><keyword xml:id="k3">Parkinson’s disease</keyword><keyword xml:id="k4">quality of life</keyword><keyword xml:id="k5">rasagiline</keyword><keyword xml:id="k6">switch</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Background: </b> The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice.</p><p><b>Methods: </b> The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined.</p><p><b>Results: </b> Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients.</p><p><b>Conclusions: </b> In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title></titleInfo><titleInfo type="abbreviated"><title>Rasagiline in daily clinical use</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease</title></titleInfo><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Reichmann</namePart><affiliation>Department of Neurology, University of Dresden, Dresden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W. H.</namePart><namePart type="family">Jost</namePart><affiliation>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2010-09</dateIssued><edition>Received 3 September 2009 Accepted 20 January 2010</edition><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">3</extent></physicalDescription><abstract lang="en">Background: The MAO‐B inhibitor rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD), and its use is supported by evidence from large‐scale, controlled clinical studies. The post‐marketing observational study presented here investigated the efficacy and tolerability of rasagiline treatment (monotherapy or combination therapy) in daily clinical practice. Methods: The study included patients with idiopathic PD who received rasagiline (recommended dose 1 mg, once daily) as monotherapy or combination therapy. The treatment and observation period was approximately 4 months. Outcome measures included the change from baseline in the Columbia University Rating Scale (CURS), the Unified PD Rating Scale fluctuation subscale, daily OFF time (patient home diaries) and the PD Questionnaire‐39. Adverse drug reactions/adverse events (ADRs/AEs) and the physician’s global judgement of tolerability and efficacy were also examined. Results: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non‐classical motor/non‐motor symptoms) and quality of life (QoL). Patients receiving combination therapy also experienced significant reductions in daily OFF time. Tolerability was rated as good/very good in over 90% of patients. Conclusions: In daily clinical practice, monotherapy or combination therapy with rasagiline is able to improve PD symptoms, reduce OFF time, and improve QoL, whilst demonstrating favourable tolerability. In addition, rasagiline has a simple dosing schedule of one tablet, once daily, with no titration. These results are consistent with the pivotal rasagiline clinical studies (TEMPO, LARGO and PRESTO).</abstract><subject lang="en"><genre>Keywords</genre><topic>combination therapy</topic><topic>monotherapy</topic><topic>Parkinson’s disease</topic><topic>quality of life</topic><topic>rasagiline</topic><topic>switch</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1164</start><end>1171</end><total>8</total></extent></part></relatedItem><identifier type="istex">5E8B3A4574D46E0EF8E935E2460D8529BBA7027B</identifier><identifier type="DOI">10.1111/j.1468-1331.2010.02986.x</identifier><identifier type="ArticleID">ENE2986</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 The Author(s). European Journal of Neurology © 2010 EFNS</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000944 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000944 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:5E8B3A4574D46E0EF8E935E2460D8529BBA7027B
|texte= Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |